Cara Therapeutics (NASDAQ:CARA) issued its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.04), Briefing.com reports. During the same quarter in the prior year, the company posted ($0.81) earnings per share.
Shares of NASDAQ CARA traded down $0.16 during mid-day trading on Friday, hitting $11.89. 416,137 shares of the stock traded hands, compared to its average volume of 870,600. Cara Therapeutics has a twelve month low of $11.11 and a twelve month high of $28.50. The company has a market cap of $393.92, a price-to-earnings ratio of -6.39 and a beta of 2.96.
Several brokerages have recently issued reports on CARA. Seaport Global Securities reiterated a “buy” rating on shares of Cara Therapeutics in a research note on Friday, March 16th. Stifel Nicolaus reiterated a “buy” rating and issued a $17.00 price target on shares of Cara Therapeutics in a research note on Wednesday, January 3rd. Zacks Investment Research lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. HC Wainwright set a $22.00 price target on Cara Therapeutics and gave the company a “buy” rating in a research note on Monday, March 19th. Finally, BidaskClub lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $24.59.
In other Cara Therapeutics news, SVP Frederique Ph.D. Menzaghi sold 15,000 shares of Cara Therapeutics stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $15.00, for a total transaction of $225,000.00. Following the transaction, the senior vice president now directly owns 122,000 shares of the company’s stock, valued at approximately $1,830,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Derek T. Chalmers sold 5,400 shares of Cara Therapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.00, for a total value of $81,000.00. Following the transaction, the chief executive officer now directly owns 1,071,392 shares in the company, valued at $16,070,880. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,900 shares of company stock worth $538,560. 7.70% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Cara Therapeutics (NASDAQ:CARA) Posts Earnings Results, Misses Estimates By $0.04 EPS” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/cara-therapeutics-cara-releases-earnings-results-misses-expectations-by-0-04-eps.html.
About Cara Therapeutics
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.